HIF1A: The Potential Drug Target and Biomarker for Anemia (G3091)

Target Name: HIF1A

NCBI ID: G3091

HIF1A

HIF1A: The Potential Drug Target and Biomarker for Anemia

Hemoglobin (HB) is a protein produced by red blood cells that carries oxygen from the lungs to the rest of the body. Anemia is a condition characterized by a low number of red blood cells or a low amount of hemoglobin. Anemia can be caused by various factors, including chronic illness, chronic blood loss, or certain medications. Treatment of anemia typically involves the administration of iron supplements or blood transfusions. However, there is a growing interest in finding new and better treatments for anemia. One potential drug target and biomarker for anemia is the HIF1A gene.

The HIF1A gene is a key regulator of the erythropoietin (EP) gene, which is responsible for producing the erythropoietin protein. The erythropoietin protein is essential for the production of red blood cells, which are responsible for carrying oxygen from the lungs to the rest of the body. The HIF1A gene plays a critical role in the regulation of the erythropoietin gene.

Research has shown that anemia is associated with increased levels of the HIF1A gene. In fact, studies have shown that individuals with anemia are typically more likely to have higher levels of the HIF1A gene than those without anemia. This is because when the body lacks oxygen, the HIF1A gene is activated to help the body produce more erythropoietin.

The HIF1A gene has also been shown to play a role in the regulation of the production of red blood cells. Studies have shown that when the HIF1A gene is activated, it can cause the production of red blood cells to increase. This is important because anemia is often caused by a lack of red blood cells, which can lead to a range of health problems, including fatigue, weakness, and shortness of breath.

The HIF1A gene is also a potential drug target for anemia because of its role in the regulation of the production of erythropoietin. erythropoietin is a protein produced by the erythropoietin gene that is responsible for producing red blood cells. The HIF1A gene has been shown to play a role in the regulation of the production of erythropoietin, which means that it may be a useful target for the treatment of anemia.

Anemia is a common condition that affects many people around the world. It is characterized by a low number of red blood cells or a low amount of hemoglobin. Anemia can be caused by various factors, including chronic illness, chronic blood loss, or certain medications. Treatment of anemia typically involves the administration of iron supplements or blood transfusions. However, there is a growing interest in finding new and better treatments for anemia. The HIF1A gene may be a drug target and biomarker for anemia, as it plays a critical role in the regulation of the production of red blood cells.

Protein Name: Hypoxia Inducible Factor 1 Subunit Alpha

Functions: Functions as a master transcriptional regulator of the adaptive response to hypoxia (PubMed:11292861, PubMed:11566883, PubMed:15465032, PubMed:16973622, PubMed:17610843, PubMed:18658046, PubMed:20624928, PubMed:22009797, PubMed:9887100, PubMed:30125331). Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia (PubMed:11292861, PubMed:11566883, PubMed:15465032, PubMed:16973622, PubMed:17610843, PubMed:20624928, PubMed:22009797, PubMed:9887100, PubMed:30125331). Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease (PubMed:22009797). Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). Activation requires recruitment of transcriptional coactivators such as CREBBP and EP300 (PubMed:9887100, PubMed:16543236). Activity is enhanced by interaction with NCOA1 and/or NCOA2 (PubMed:10594042). Interaction with redox regulatory protein APEX1 seems to activate CTAD and potentiates activation by NCOA1 and CREBBP (PubMed:10202154, PubMed:10594042). Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia (PubMed:19528298)

The "HIF1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIF1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets